<DOC>
	<DOCNO>NCT00949949</DOCNO>
	<brief_summary>This randomized phase I trial study side effect best dose everolimus , gemcitabine hydrochloride , cisplatin treat patient unresectable solid tumor refractory standard therapy . Drugs use chemotherapy , everolimus , gemcitabine hydrochloride , cisplatin , work different way stop growth tumor cell , either kill cell stop divide . Giving one drug ( combination chemotherapy ) may kill tumor cell .</brief_summary>
	<brief_title>Everolimus , Gemcitabine Hydrochloride , Cisplatin Treating Patients With Unresectable Solid Tumors Refractory Standard Therapy</brief_title>
	<detailed_description>OBJECTIVES : I . To determine maximally tolerate dose ( MTD ) concurrently administer everolimus gemcitabine ( gemcitabine hydrochloride ) patient advance , refractory solid tumor ( two-agent MTD ) . II . To determine maximally tolerate dose concurrently administer everolimus , gemcitabine cisplatin patient advance , refractory solid tumor ( three-agent MTD ) . III . To describe toxicity two treatment combination . IV . To describe evidence antitumor activity two treatment combination . V. To obtain pilot data toxicity efficacy outcome everolimus , gemcitabine cisplatin patient cholangiocarcinoma gallbladder carcinoma . ( Cohort III ) OUTLINE : This dose-escalation study gemcitabine hydrochloride everolimus . COHORT I : Patients receive gemcitabine hydrochloride intravenously ( IV ) 30 minute day 1 8 everolimus orally ( PO ) daily 3 time weekly . COHORT II : Patients receive gemcitabine hydrochloride IV 30 minute cisplatin IV 1 hour day 1 8 everolimus PO daily 3 time weekly . COHORT III : Patients receive treatment cohort II . Courses repeat every 21 day absence disease progression unacceptable toxicity . After completion study treatment , patient follow 3 month .</detailed_description>
	<mesh_term>Cholangiocarcinoma</mesh_term>
	<mesh_term>Gallbladder Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Histologic proof cancer unresectable refractory refuse standard treatment disease ; exception : cancer gemcitabine consider appropriate initial treatment option Cohort III ( MTD ) Only : Patients histologic proof metastatic cholangiocarcinoma gallbladder carcinoma previous treatment metastatic disease receive gemcitabine &gt; = 6 month ago part adjuvant therapy Absolute neutrophil count ( ANC ) &gt; = 1500/uL Platelet ( PLT ) &gt; = 100,000/uL Total bilirubin = &lt; 1.5 x Institutional upper limit normal ( ULN ) Alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) = &lt; 2.5 x upper limit normal ( ULN ) ( = &lt; 5x ULN patient liver metastasis ) Creatinine = &lt; 1.5 x Institutional ULN Alkaline phosphatase = &lt; 5 x Institutional ULN Hemoglobin ( Hgb ) &gt; = 9.0 g/dL International normalized ratio ( INR ) Partial thromboplastin time ( PTT ) = &lt; 3.0 x ULN ( anticoagulation allow target INR = &lt; 3.0 x ULN stable dose warfarin stable dose lowmolecularweight [ LMW ] heparin &gt; 2 week time registration ) Fasting serum glucose &lt; 1.5 x ULN Fasting serum cholesterol = &lt; 300 mg/dL OR = &lt; 7.75 mmol/L AND fast triglyceride = &lt; 2.5 x ULN ; NOTE : In case one threshold exceed , patient include initiation appropriate lipid lower medication Eastern Cooperative Oncology Group ( ECOG ) Performance Status ( PS ) 0 , 1 2 Ability provide inform consent Willingness return Mayo Clinic follow Life expectancy &gt; = 12 week Women childbearing potential : Negative serum pregnancy test do = &lt; 7 day prior registration Known standard therapy patient 's disease potentially curative definitely capable extend life expectancy Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement Clinically significant cardiac disease , especially history myocardial infarction = &lt; 6 month , congestive heart failure ( New York Heart Association [ NYHA ] classification III IV ) require use ongoing maintenance therapy lifethreatening ventricular arrhythmia Patients take strong inhibitor inducer CYP3A4 Prior therapy everolimus Any follow prior therapy : Chemotherapy = &lt; 4 week prior registration Mitomycin C/nitrosoureas = &lt; 6 week prior registration Immunotherapy = &lt; 4 week prior registration Biological therapy = &lt; 4 week prior registration Radiation therapy = &lt; 4 week prior registration Radiation &gt; 25 % bone marrow prior registration Failure fully recover acute , reversible effect prior chemotherapy regardless interval since last treatment CNS metastases stable least 4 week prior registration base imaging , clinical assessment , use steroid Uncontrolled brain leptomeningeal metastasis , include patient continue require glucocorticoid brain leptomeningeal metastasis Pregnant woman Nursing woman Men woman childbearing potential unwilling employ adequate contraception Other concurrent chemotherapy , immunotherapy , radiotherapy , ancillary therapy consider investigational ( utilized nonFood Drug Administration [ FDA ] approve indication context research investigation ) Comorbid systemic illness severe concurrent disease , judgment investigator , would make patient inappropriate entry study interfere significantly proper assessment safety toxicity prescribe regimen Immunocompromised patient ( relate use corticosteroid ) include patient know human immunodeficiency virus ( HIV ) positive Current active malignancy , except nonmelanoma skin cancer carcinomainsitu cervix Impairment gastrointestinal function gastrointestinal disease may significantly alter absorption everolimus ( e.g. , ulcerative disease , uncontrolled nausea , vomit , diarrhea , malabsorption syndrome small bowel resection ) Severely impaired lung function ( i.e. , force expiratory volume one second [ FEV1 ] &lt; 1 liter ) Received immunization attenuate live vaccine = &lt; 7 day prior study entry study period ; NOTE : close contact receive attenuated live vaccine avoid treatment everolimus ; example live vaccine include intranasal influenza , measles , mumps , rubella , oral polio , BCG , yellow fever , varicella TY21a typhoid vaccine Liver disease cirrhosis severe hepatic impairment ( ChildPugh class C ) ; Note : A detailed assessment Hepatitis B/C medical history risk factor must do screening patient ; hepatitis B virus ( HBV ) deoxyribonucleic acid ( DNA ) hepatitis C virus ( HCV ) ribonucleic acid ( RNA ) polymerase chain reaction ( PCR ) test require screening patient positive medical history base risk factor and/or confirmation prior HBV/HCV infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>